Propanc Biopharma, Inc.
PPCBNasdaq
$1.49
↓ -6.3%Jul 17 close · end-of-day
Price
1Y↓ -98.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3M
Enterprise Value
$1.4M
P/E
0.9
P/S
—
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$18.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-186.8%
ROIC
-146.9%
Debt / Equity
0.0
Net Cash
-$55,000.00
Return 1Y
+645.0%
Company profile
Propanc Biopharma focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1
- Website
- propanc.com
Earnings
PPCB Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$7.09↓ -97.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.8M | -$2.0M | -$1.8M | -$1.5M | -$57.3M |
| Net income | -$2.0M | -$2.7M | -$2.7M | -$1.8M | -$58.9M |
| Diluted EPS | — | -$49.23 | -$1.80 | -$35,324.35 | -$371.22 |
| Operating cash flow | -$1.1M | -$1.4M | -$1.1M | -$935,118.00 | -$405,168.00 |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q '24 | Q '25 | Q4 '25 | Q1 '25 | Q '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$259,899.00 | -$290,790.00 | -$213,382.00 | -$53.1M | -$3.6M | -$4.7M | -$3.7M | -$6.4M |
| Net income | -$358,578.00 | -$354,310.00 | -$430,183.00 | -$54.1M | -$4.1M | -$4.8M | -$3.1M | -$6.4M |
| Diluted EPS | -$33,218.97 | -$35.97 | -$32.23 | -$312.46 | $9.44 | -$0.39 | -$0.30 | -$7.09 |
| Operating cash flow | -$259,966.00 | -$235,515.00 | $18,729.00 | -$96,196.00 | -$92,186.00 | -$1.9M | -$999,140.00 | -$1.1M |
| Free cash flow | — | — | — | — | — | -$1.9M | -$1.0M | -$1.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 2, 2026
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.